Takeda CSO Chris Arendt on Transforming Drug Discovery & the R&D Pipeline
Inside the ICE House
•
18m
Takeda is entering one of the most pivotal moments in its 245-year history, with a late-stage pipeline poised to transform patient outcomes across three therapeutic areas. Chief Scientific Officer Chris Arendt goes Inside the ICE House to discuss the science behind drug candidates targeting narcolepsy, polycythemia vera, and psoriasis. He explores how AI and computational technologies are reshaping drug discovery and why building the right data foundation is critical to supercharging Takeda's R&D engine.
Up Next in Inside the ICE House
-
KKR's Pete Stavros on Ownership, Oppo...
Pete Stavros returns to Inside the ICE House three years after his first appearance, as Ownership Works enters its fourth year of driving inclusive capitalism. The initiative has scaled across industries, giving employees a stake in the success they help create. Stavros reflects on the journey, t...
-
IBM's Noah Syken Augments the Action ...
Noah Syken, Vice President of Sports and Entertainment Partnerships at IBM (NYSE: IBM), gave us an exclusive peek behind the curtain of IBM’s Command at the Billie Jean King USTA National Tennis Center at this year’s US Open. Noah shared how technology and A.I. are transforming the way sports eve...
-
Saving the World: Michel Paradis Deta...
On June 5, 1944, Supreme Allied Commander Dwight Eisenhower addressed 150,000 soldiers boldly poised to invade France and liberate Europe. “The eyes of the world are upon you,” the general intoned. Eighty years later, Michel Paradis’ new book, “THE LIGHT OF BATTLE: Eisenhower, D-Day, and the Birt...
